Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure

• Status: Completed
• Trial end date: 2012-12-01

Summary

Primary Objective:

• To assess the efficacy of insulin glargine as measured by changes of HbA1c levels from baseline in type 2 diabetes mellitus (T2DM) patients following GLP-1 failure.

Secondary Objective:

• To determine the change in glycemic control, safety, and treatment satisfaction in insulin glargine use in patients following GLP-1 failure.

• Phase: Phase 4

Details

• Lead Sponsor: Sanofi
• Treatments: Glucagon; Glucagon-Like Peptide 1; Insulin; Insulin Glargine; Insulin, Globin Zinc